Phio Pharmaceuticals Corp. (PHIO)
After hours:
| Previous close | 0.7603 |
| Open | 0.8200 |
| Bid | 0.7497 x 100 |
| Ask | 0.8276 x 100 |
| Day's range | 0.7504 - 0.8350 |
| 52-week range | 0.5000 - 5.2900 |
| Volume | |
| Avg. volume | 428,387 |
| Market cap | 3.613M |
| Beta (5Y monthly) | 1.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.2000 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.00 |
GlobeNewswirePhio Pharmaceuticals Secures New Investor
--Fund invests in microcap equitiesMARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has entered into a purchase agreement with TRITON Funds. Subject to the terms of the purchase agreement, TRITON will purchase up to approximately 18.8% of Phio’s common shares yiel
- GlobeNewswire
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)
-Phio’s lead candidate, PH-762, targets PD-1, a critical target in cutaneous carcinomaMARLBOROUGH, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting data about its lead clinical candidate, PH-762, an INTASYL compound. The data is being presented in three posters a
- GlobeNewswire
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
-PH-762 is Phio’s lead product candidate -Screening on the next cohort is on-going MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced progress on its Phase 1b clinical study for their lead compound PH-762. Dosing of the first cohort of patients was completed and screen
